112 related articles for article (PubMed ID: 32890988)
1. Novel 2'-alkoxymethyl substituted klavuzon derivatives as inhibitors of Topo I and CRM1.
Çetinkaya H; Yıldız MS; Kutluer M; Alkan A; Ozan Otaş H; Çağır A
Bioorg Chem; 2020 Oct; 103():104162. PubMed ID: 32890988
[TBL] [Abstract][Full Text] [Related]
2. CRM1 inhibitory and antiproliferative activities of novel 4'-alkyl substituted klavuzon derivatives.
Kanbur T; Kara M; Kutluer M; Şen A; Delman M; Alkan A; Otaş HO; Akçok İ; Çağır A
Bioorg Med Chem; 2017 Aug; 25(16):4444-4451. PubMed ID: 28689976
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative activity of (R)-4'-methylklavuzon on hepatocellular carcinoma cells and EpCAM
Delman M; Avcı ST; Akçok İ; Kanbur T; Erdal E; Çağır A
Eur J Med Chem; 2019 Oct; 180():224-237. PubMed ID: 31306909
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Topoisomerase I inhibitory properties of klavuzon derivatives.
Akçok İ; Mete D; Şen A; Kasaplar P; Korkmaz KS; Çağır A
Bioorg Chem; 2017 Apr; 71():275-284. PubMed ID: 28242062
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of aryl-substituted naphthalenoids as potent topoisomerase inhibitors.
Shen Y; Chen W; Li Z; Shen Y
Med Chem; 2014; 10(5):533-9. PubMed ID: 24047216
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, Biological Evaluation and Molecular Docking Study of Cyclic Diarylheptanoids as Potential Anticancer Therapeutics.
Lu Y; Yin W; Alam MS; Kadi AA; Jahng Y; Kwon Y; Rahman AFMM
Anticancer Agents Med Chem; 2020; 20(4):464-475. PubMed ID: 31763968
[TBL] [Abstract][Full Text] [Related]
7. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103.
Etiévant C; Kruczynski A; Barret JM; Perrin D; van Hille B; Guminski Y; Hill BT
Cancer Chemother Pharmacol; 2000; 46(2):101-13. PubMed ID: 10972479
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents.
Madadi NR; Penthala NR; Ketkar A; Eoff RL; Trujullo-Alonso V; Guzman ML; Crooks PA
Anticancer Agents Med Chem; 2018; 18(4):556-564. PubMed ID: 28403783
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase II binds importin alpha isoforms and exportin/CRM1 but does not shuttle between the nucleus and cytoplasm in proliferating cells.
Mirski SE; Sparks KE; Friedrich B; Köhler M; Mo YY; Beck WT; Cole SP
Exp Cell Res; 2007 Feb; 313(3):627-37. PubMed ID: 17182034
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
[TBL] [Abstract][Full Text] [Related]
11. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer.
Noske A; Weichert W; Niesporek S; Röske A; Buckendahl AC; Koch I; Sehouli J; Dietel M; Denkert C
Cancer; 2008 Apr; 112(8):1733-43. PubMed ID: 18306389
[TBL] [Abstract][Full Text] [Related]
12. Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and IIα dual inhibitors with DNA non-intercalative catalytic activity.
Bist G; Park S; Song C; Thapa Magar TB; Shrestha A; Kwon Y; Lee ES
Eur J Med Chem; 2017 Jun; 133():69-84. PubMed ID: 28384547
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
[TBL] [Abstract][Full Text] [Related]
14. In vivo antitumor activity of F 11782, a non-intercalating dual catalytic inhibitor of topoisomerases I and II, against a panel of human tumor xenografts.
Kruczynski A; Ricome C; Waud WR; Hill BT
J Exp Ther Oncol; 2002; 2(4):219-27. PubMed ID: 12416026
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors.
Yao BL; Mai YW; Chen SB; Xie HT; Yao PF; Ou TM; Tan JH; Wang HG; Li D; Huang SL; Gu LQ; Huang ZS
Eur J Med Chem; 2015 Mar; 92():540-53. PubMed ID: 25599951
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological research of novel N-phenylbenzamide-4-methylamine acridine derivatives as potential topoisomerase I/II and apoptosis-inducing agents.
Zhang B; Dou Z; Xiong Z; Wang N; He S; Yan X; Jin H
Bioorg Med Chem Lett; 2019 Dec; 29(23):126714. PubMed ID: 31635931
[TBL] [Abstract][Full Text] [Related]
17. Development of 13H-benzo[f]chromeno[4,3-b][1,7]naphthyridines and their salts as potent cytotoxic agents and topoisomerase I/IIα inhibitors.
Arepalli SK; Lee C; Sim S; Lee K; Jo H; Jun KY; Kwon Y; Kang JS; Jung JK; Lee H
Bioorg Med Chem; 2018 Oct; 26(18):5181-5193. PubMed ID: 30253887
[TBL] [Abstract][Full Text] [Related]
18. Discovery of DNA Topoisomerase I Inhibitors with Low-Cytotoxicity Based on Virtual Screening from Natural Products.
Xin LT; Liu L; Shao CL; Yu RL; Chen FL; Yue SJ; Wang M; Guo ZL; Fan YC; Guan HS; Wang CY
Mar Drugs; 2017 Jul; 15(7):. PubMed ID: 28698495
[TBL] [Abstract][Full Text] [Related]
19. Modification of 3-arylisoquinolines into 3,4-diarylisoquinolines and assessment of their cytotoxicity and topoisomerase inhibition.
Khadka DB; Woo H; Yang SH; Zhao C; Jin Y; Le TN; Kwon Y; Cho WJ
Eur J Med Chem; 2015 Mar; 92():583-607. PubMed ID: 25613224
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Bridewell DJ; Finlay GJ; Baguley BC
Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
